Registry Following People With Tumors Behind the Abdominal Lining
Collects health records and outcomes of people with retroperitoneal tumors over time.
Plain-language title generated from the registry record
Registry title: Retroperitoneal Tumor Registry
Key facts
- Where
- Changchun, ChinaSee the site
Where in China
- The First Hospital of Jilin UniversityChangchun, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Hospital of Jilin University
- Trial code
- NCT07915895
- Record updated
- 4 November 2026
- Original description
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant treatment, surgical complications, recurrence, metastasis, and long-term survival data. The registry will summarize clinical features, evaluate surgical outcomes, and explore prognostic factors of retroperitoneal tumors. Written informed consent will be obtained from all participants prior to enrollment.Read full original descriptionShow less
Retroperitoneal Tumor Registry: A Real-world Cohort Study of Clinical Features, Surgical Outcomes and Long-term Survival
This is an observational, real-world registry study. The RETROR registry aims to establish a clinical database for patients with retroperitoneal tumors. We will systematically collect demographic information, comorbidities, preoperative imaging findings, perioperative parameters, pathological outcomes, adjuvant treatment, surgical complications, recurrence, metastasis, and long-term survival data. The registry will summarize clinical features, evaluate surgical outcomes, and explore prognostic factors of retroperitoneal tumors. Written informed consent will be obtained from all participants prior to enrollment.
Inclusion: Patients with preoperative imaging or pathological diagnosis of retroperitoneal tumors, with no restriction on age and gender.
Exclusion: Patients with psychiatric or neurological disorders who cannot express their will properly; Patients who are unable to understand the study protocol and refuse to participate or sign the informed consent form.